拜瑪林製藥 BMRN 深 滬
等待開盤 10-24 09:30:00 美东时间
54.55
+1.180
+2.21%
華盛通- 最 高54.61
- 今 開53.485
- 成交量 234.35万股
- 最 低 53.14
- 昨 收 53.37
- 總市值 104.74亿
- 52周最高 73.51
- 市盈率 靜 24.71
- 換手率 1.22%
- 52周最低 51.565
- 委 比 -36.65%
- 總股本 1.92亿
- 歷史最高 151.75
- 量 比 1.13
- 振 幅 2.75%
- 歷史最低 23.735
- 每 手 1
- 風險率 5.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biomerica Reports First Quarter Fiscal 2026 Financial Results
Biomerica reported Q1 FY2026 financial results with net sales of $1.4 million, a decrease compared to $1.8 million in Q1 FY2025, due to reduced retail activity and international order timing. Despite lower sales, gross margin improved to 31% from 16% due to higher-margin product mix. Operating expenses declined to $1.5 million from $1.7 million, reflecting cost reduction efforts. The company achieved a net profit of approximately $2,000, compared...
10-15 13:27
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
Is BioMarin Pharmaceutical Inc Gaining or Losing Market Support?
BioMarin Pharmaceutical Inc's (NYSE:BMRN) short interest as a percent of float ...
10-10 03:00
BioMarin Pharmaceutical Expects Q3 Will Include Acquired IPR&D Charges Of ~$221M On A Pre-Tax Basis Due To Inozyme Pharma Deal; For Q3, Co Expects Charge Of About $1.10 To Both GAAP And Non-GAAP EPS Due To Inozyme Pharma Deal
https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/bmrn-20251007.htm
10-08 05:25
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion Inc., a clinical-stage diabetes and obesity medicines company, announced on September 24, 2025, that its compensation committee granted one new employee non-qualified stock options to purchase 48,000 shares of the Company’s common stock. The shares will vest quarterly over four years, contingent on continued employment, under the 2023 Inducement Equity Plan, which aligns with Nasdaq Listing Rule 5635(c)(4). Biomea Fusion focuses on ...
10-01 11:00
On Saturday, BioMarin Pharmaceutical Announced New Data Characterizing The Efficacy And Safety Of Palynziq (Pegvaliase-pqpz) For Adolescents With Phenylketonuria
New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQBioMarin's planned submission to global health authorities on track for second
09-08 00:24
What's Driving the Market Sentiment Around BioMarin Pharmaceutical?
BioMarin Pharmaceutical's (NYSE:BMRN) short percent of float has fallen 3.68% s...
08-30 03:00
“30年一遇”的估值洼地！Evercore ISI：美股医疗股正上演历史性熊市反弹 或是更大牛市前兆
Evercore ISI分析师表示，医疗保健板块近期显现初步复苏信号。此前，该板块相对于标普500指数的估值折价幅度创下30年来新高。
08-20 08:56
Health care stocks show signs of recovery after prolonged slump – Evercore ISI
The health care sector (NYSEARCA:XLV) is showing early signs of recovery after experiencing its largest valuation discount to the S&P 500 (SP500) in 30 years, according to Evercore ISI analysts. Since...
08-20 03:48
